首页> 外文OA文献 >Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF

【2h】

Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF

机译：在成年人的一项随机，开放标签，3b期非劣效性试验中，HIV感染成人的症状报告，在超过48周的时间里，他们改用共同配制的Elvitegravir，Cobicistat，恩曲他滨和Tenofovir DF，与继续使用Ritonavir-Boosted蛋白酶抑制剂联合Emtricitabine和Tenofovir继续治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF [J] . Gathe Joseph, Arribas Jose R., Van Lunzen Jan, The patient . 2015,第5期

机译：在成人，随机，开放标签，3b期非劣性HIV感染成人试验中，在48周内患者报告的症状转为使用共同配制的Elvitegravir，Cobicistat，恩曲他滨和替诺福韦DF，与利托那韦增强蛋白酶抑制剂与恩曲他韦和替诺福的继续
2. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF [J] . Joseph Gathe, Jose R. Arribas, Jan Lunzen, The Patient - Patient-Centered Outcomes Research . 2015,第5期

机译：在成年人的一项随机，开放标签，3b期非劣效性试验中，HIV感染成人的症状报告，在超过48周的时间里，他们改用共同配制的Elvitegravir，Cobicistat，恩曲他滨和Tenofovir DF，与继续使用Ritonavir-Boosted蛋白酶抑制剂联合Emtricitabine和Tenofovir继续治疗
3. Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF [J] . Mills Anthony, Garner Will, Pozniak Anton, The patient . 2015,第4期

机译：艾滋病毒成年人转为共同配制的Elvitegravir，Cobicistat，恩曲他滨和Tenofovir DF的随机，开放标签，IIIb期非劣效性试验在超过48周的患者报告症状与继续使用恩曲他滨的非核苷逆转录酶抑制剂的比较和替诺福韦DF
4. Patient-Reported Symptoms over 48 Weeks in a Randomized Open-Label Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir Cobicistat Emtricitabine and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF [O] . Joseph Gathe, Jose R. Arribas, Jan Van Lunzen, -1

机译：在成年人的一项随机开放标签3b期非劣效性试验中HIV感染成人的症状报告在超过48周的时间里他们改用共同配制的ElvitegravirCobicistat恩曲他滨和Tenofovir DF与继续使用Ritonavir-Boosted蛋白酶抑制剂联合Emtricitabine和Tenofovir继续治疗
5. Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF [O] . Anthony Mills, Will Garner, Anton Pozniak, 2015

机译：艾滋病毒成人转而使用共同配制的Elvitegravir，Cobicistat，恩曲他滨和Tenofovir DF的随机，开放标签，IIIb期非劣效性试验在超过48周的患者报告症状与继续使用恩曲他滨的非核苷逆转录酶抑制剂的比较和替诺福韦DF

Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF

著录项

相似文献

相关主题

期刊订阅